Literature DB >> 1688820

Acute myeloid leukemia in elderly adults.

J Tucker1, A E Thomas, W M Gregory, T S Ganesan, S T Malik, J A Amess, J Lim, L Willis, A Z Rohatiner, T A Lister.   

Abstract

One hundred and fifteen previously untreated adults aged over 60 years were referred to St Bartholomew's Hospital between 1978 and 1986 for management of acute myeloid leukemia (AML). Twenty-seven patients received symptomatic or palliative treatment only because combination chemotherapy was considered inappropriate. Eighty-eight patients received intensive chemotherapy with curative intent. There was a 48 per cent 'early death' rate and a 24 per cent incidence of resistant disease; complete remission (CR) was achieved in 25/88 patients (28 per cent). By multivariate analysis, a blast count less than 50 x 10(9)/l at presentation was the only factor predictive for achievement of CR whilst the latter and a presentation blast count less than 50 x 10(9)/l predicted for superior survival. Treatment was often curtailed on account of unacceptable toxicity; only 2/88 patients received the planned six cycles of treatment. Two patients died in CR. Four patients are alive in first CR at 3-9 years from treatment; one is alive in second CR following meningeal relapse. Overall survival was significantly worse than that of a contemporaneous group of adults aged 15-59 years treated at this hospital, but duration of CR was comparable. There are great difficulties involved in the intensive treatment of AML in elderly adults, but the major survival benefit gained by achieving CR should stimulate the search for better tolerated but still curative regimens.

Entities:  

Mesh:

Year:  1990        PMID: 1688820     DOI: 10.1002/hon.2900080103

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  4 in total

Review 1.  Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia.

Authors:  S Bolam; T Hamblin
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 2.  Acute myeloid leukemia in the elderly: biological features and search for adequate treatment.

Authors:  V Heinemann; U Jehn
Journal:  Ann Hematol       Date:  1991-10       Impact factor: 3.673

3.  Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic models.

Authors:  Antoine J Harb; Wei Tan; Gregory E Wilding; LaurieAnn Ford; Sheila N J Sait; AnneMarie W Block; Maurice Barcos; Paul K Wallace; Eunice S Wang; Meir Wetzler
Journal:  Cancer       Date:  2009-06-01       Impact factor: 6.860

4.  Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients.

Authors:  P K MacCallum; A Z Rohatiner; C L Davis; J S Whelan; A M Oza; J Lim; S Love; J A Amess; M Leahy; R K Gupta
Journal:  Ann Hematol       Date:  1995-07       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.